Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Immatics logo — The Global Leader in Precision Targeting of PRAME

Immatics

The Global Leader in Precision Targeting of PRAME

Founded 2000 Germany Germany 637 employees IPO Total: $908.10M

General Information

Company Name Immatics
Founded Year 2000
Location Germany Germany +3
Employees 637
Funding Stage IPO
Social

Get notified when Immatics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Immatics

Immatics, founded in 2000 and headquartered in Germany, positions itself as a crucial player in the biotechnology sector. As the self-proclaimed "The Global Leader in Precision Targeting of PRAME", the company focuses on cancer treatment with a specialty in targeting PRAME—a protein expressed in over 50 types of cancer.

The company's innovation is centered around its comprehensive PRAME franchise, which includes both TCR T-cell therapies and TCR bispecifics. Their advanced clinical pipeline, featuring the broadest array of PRAME indications and modalities, reflects a commitment to revolutionizing cancer treatment.

The company secured a significant $125.00M Post IPO Equity investment on 01 December 2025, indicating strong investor confidence in its long-term vision and scientific advancements. For investors, Immatics represents a promising venture with substantial potential to impact the global oncology landscape.

Taxonomy: Precision Medicine, Cancer Immunotherapy, TCR T-cell Therapies, TCR Bispecifics, Adoptive Cell Therapy, PRAME Targeting, Solid Tumor Treatment, Peptidomics, Tumor-associated Peptides, Biopharmaceutical, Clinical Pipeline, HLA-restricted Target Discovery, Cancer Biomarkers, Bispecific Development, TCR Discovery

Services & Products

Precision targeting of PRAME in over 50 types of cancer
Development of cell therapies and bispecific products

Target Customers

Cancer patients with unmet medical needs Healthcare professionals specializing in oncology Research and academic institutions

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 Dec 2025
Post Ipo Equity •••••• - 01 Oct 2024
Private Placement Vc •••••• 1
Investor
01 Jul 2023
Post Ipo Equity •••••• 12
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
01 Oct 2022
Spac Private Placement •••••• 1
Investor
01 Jul 2020

View All 14 Funding Rounds

Immatics Alternatives & Competitors

View All Alternatives
Immatics vs
T Cell Nouveau
T Cell Nouveau Japan

Clinical stage biopharmaceutical company with novel TCR like CAR-T cell therapy for solid tumors at...

1 employees
Biopharma, Biotechnology
Compare Immatics vs T Cell Nouveau
Immatics vs
T-knife Therapeutics
T-knife Therapeutics United States

T-knife uses a mouse platform to create human TCRs for cancer treatment without modification.

Series B
78 employees
Compare Immatics vs T-knife Therapeutics
Immatics vs
Mongoose Bio Inc.
Mongoose Bio Inc. United States

Delivering clinically proven epigenetically programmed memory TCR-T cells

Seed
3 employees
Compare Immatics vs Mongoose Bio Inc.
View all alternatives

FAQ About Immatics

The Global Leader in Precision Targeting of PRAME
Immatics was founded in 2000.
Immatics is headquartered in Germany.
Immatics has approximately 637 employees.
Immatics has completed 14 funding rounds, raising a total of $908.10M. The latest funding stage is IPO.
Immatics offers: Precision targeting of PRAME in over 50 types of cancer, Development of cell therapies and bispecific products.
Top alternatives and competitors to Immatics include T Cell Nouveau, T-knife Therapeutics, Mongoose Bio Inc., Affini-T Therapeutics, Cytovant Sciences Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immatics and T Cell Nouveau are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Immatics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy